# Efficacy and Safety of Golidocitinib for Rapidly Progressive Interstitial Lung Disease

> **NCT07737249** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Interstitial Lung Diseases

## Interventions

- **DRUG:** golidocitinib plus corticosteroid
- **DRUG:** non-JAK inhibitor immunosuppressant plus corticosteroid

## Key facts

- **NCT ID:** NCT07737249
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2027-08-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07737249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07737249, "Efficacy and Safety of Golidocitinib for Rapidly Progressive Interstitial Lung Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07737249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*